Introduction {#section1-1479973119900612}
============

Cystic fibrosis (CF) is a genetic disease with clinical manifestations that result from involvement of multiple organ systems, most notably the lungs and gastrointestinal tract, which can lead to respiratory failure and exocrine pancreatic insufficiency (EPI), respectively.^[@bibr1-1479973119900612]^ EPI is present in 85% to 90% of patients with CF^[@bibr2-1479973119900612]^; the lack of pancreatic enzymes in these patients leads to maldigestion and malabsorption^[@bibr3-1479973119900612],[@bibr4-1479973119900612]^ contributing to poor nutritional status.^[@bibr5-1479973119900612]^ In children with CF, reduced lung function is associated with frequent hospitalization and poor nutritional status,^[@bibr6-1479973119900612],[@bibr7-1479973119900612]^ whereas nutritional status is positively associated with lung function and survival in pediatric patients and young adults with CF.^[@bibr7-1479973119900612],[@bibr8-1479973119900612]^

Complicated and time-consuming treatment regimens, which may result in low adherence to medications, are a challenge in the management of patients with CF.^[@bibr9-1479973119900612]^ Low adherence to pulmonary medications in patients with CF is associated with more frequent pulmonary exacerbations^[@bibr10-1479973119900612]^ and more CF-related hospitalizations and higher health-care costs,^[@bibr11-1479973119900612]^ all of which may result in reduced health care-related quality of life.^[@bibr12-1479973119900612]^ In addition to pulmonary medications, more than 80% of patients with CF younger than 40 years are prescribed pancreatic enzyme replacement therapy (PERT) to treat EPI.^[@bibr13-1479973119900612]^ Low adherence to PERT is a common cause of ongoing malnutrition despite prescriptions of appropriate doses in patients with CF.^[@bibr14-1479973119900612]^ Malnutrition in CF may require surgical placement of a gastrostomy tube in order to provide enteral nutrition therapy^[@bibr15-1479973119900612],[@bibr16-1479973119900612]^ or for the short-term placement of a peripherally inserted central catheter for total parenteral nutrition.^[@bibr16-1479973119900612]^ The high cost and associated morbidities of these treatments are well documented.^[@bibr15-1479973119900612]^ Managing complications of malabsorption or malnutrition in patients with CF often requires hospitalization.

The relationship between reported adherence to PERT and health-care utilization in children and adults with CF is not well-studied. Because of the importance of medication adherence to clinical outcomes, nutritional status, hospitalization, and quality of life, our objective was to investigate the relationship of PERT use rates and annual all-cause hospital admission rates (HARs), annual total hospital nights (THNs), and body mass index (BMI) in children and adults with EPI due to CF. We also evaluated the influence of nutritional status on hospitalizations in patients with CF. We used data from the CF Foundation (CFF) Patient Registry, which was established in 1966 and contained information on 28,676 patients with CF as of 2014.^[@bibr13-1479973119900612]^ The registry is used to track trends in patient care and outcomes, facilitate the design of clinical trials, conduct epidemiologic research, and execute post-marketing studies.

Methods {#section2-1479973119900612}
=======

Data source {#section3-1479973119900612}
-----------

We performed a retrospective analysis of the CFF Patient Registry using data from 2000 to 2012 for pediatric patients and from 2000 to 2013 for adults.^[@bibr17-1479973119900612],[@bibr18-1479973119900612]^ To be included in the analysis, pediatric patients had to have been born in or after 2000, have been diagnosed with CF between 2000 and 2007, and have received PERT during at least their final year of enrollment in the CFF Patient Registry. Adult patients were ≥20 years of age and had to have at least one dose of PERT reported during at least their final year of enrollment in the CFF Patient Registry. Pediatric and adult patients were excluded from analysis if their only registry record was in the year of their death; patients with anomalous data (i.e. THN \>365 days in a year or impossible timing of diagnosis or referral (diagnosis of CF in a year before birth year, review before diagnosis, review before birth)) were also excluded. By design, in order to focus specifically upon the separate pediatric and adult populations, no analyses were conducted in adolescent patients 14 to 19 years of age. Pancreatic status (sufficient vs. insufficient) is not captured in the registry.

Assessments {#section4-1479973119900612}
-----------

The self-reported annual PERT use rate (adherence) was defined as the percentage of CF center outpatient visits per year at which PERT use was recorded as being used for each patient. Annual HAR was the number of inpatient care episodes reported per year in the CF registry for each patient. If there was no hospitalization record for a particular review year, the assumption was that the days of hospitalization for that year were zero. The annual THN was calculated as the sum of the total hospital nights reported for each patient encounter in a given year for each patient.

Statistical analysis {#section5-1479973119900612}
--------------------

The data were evaluated using two general approaches: cumulative longitudinal patient-level data and cross-sectional data at discrete time points. A cumulative longitudinal analysis was used to evaluate and summarize patient level data over the entire analysis period. A cross-sectional analysis was used to evaluate pediatric patient-level data at discrete time points, specifically age in years. The mean annual PERT use rate, cumulative PERT use rate, annual HAR, and annual THN were calculated for each patient. Multivariate linear regression, correlation analysis, and graphical methods were used to determine the association of annual HAR and THN with the mean annual PERT use rate, cumulative PERT use rate, mean BMI (in adults) or BMI percentile (BMI%, which is more appropriate for children^[@bibr19-1479973119900612]^), age, and sex.

Results {#section6-1479973119900612}
=======

Patients and PERT use {#section7-1479973119900612}
---------------------

After excluding patients with anomalous data, 5301 children with CF met the inclusion criteria and were included in the analysis ([Figure 1](#fig1-1479973119900612){ref-type="fig"}). For adults, 16,994 adults were identified after excluding patients with anomalous data, as above, and those who died during their final year of enrollment in the CFF Patient Registry ([Figure 1](#fig1-1479973119900612){ref-type="fig"}). Of these adults, 13,989 used at least 1 dose of PERT in their final year of enrollment in the CFF Patient Registry and were included in the analysis. The mean follow-up was 6.9 years for children and 5.3 years for adults ([Table 1](#table1-1479973119900612){ref-type="table"}). Averaged over all review years, the median annual PERT use was 87% (range, 5--100%; [Table 1](#table1-1479973119900612){ref-type="table"}) in children and 80% (range, 0.02--100%) in adults.

![Disposition of CFF registry patients with cystic fibrosis. CFF: Cystic Fibrosis Foundation..](10.1177_1479973119900612-fig1){#fig1-1479973119900612}

###### 

Characteristics of the analysis populations.

![](10.1177_1479973119900612-table1)

  Characteristic                              Pediatric patients (*N* = 5301)   Adult patients (*N* = 13,989)
  ------------------------------------------- --------------------------------- -------------------------------
  Male, *n* (%)                               2610 (49.2)                       7667 (54.8)
  Follow-up, years                                                              
   Mean ± SD                                  6.9 ± 1.6                         5.3 ± 2.9
   Median (range)                             8 (1--8)                          5 (1--9)
  Age at CF diagnosis, years                                                    
   Mean ± SD                                  1.6 ± 1.2                         5.6 ± 9.6
   Median (range)                             1 (1--8)                          2 (1--82)
  Over all review years                                                         
   BMI,^a^ kg/m^2^                                                              
   Mean ± SD                                  ---                               21.8 ± 3.5
   Median (range)                             ---                               21.3 (12.4--44.8)
  BMI%^b^                                                                       
   Mean ± SD                                  52.3 ± 21.7                       
   Median (range)                             52.7 (0--100)                     
  Annual PERT use rate, %                                                       
   Mean ± SD                                  83 ± 15                           77 ± 20
   Median (range)                             87 (5--100)                       80 (0.02--100)
  Cumulative PERT use, years^c^                                                 
   Mean ± SD                                  5.7 ± 1.6                         4.0 ± 2.4
   Median (range)                             5.9 (0.05--8)                     3.8 (0.02--9.0)
  Cumulative number of years of PERT use^d^                                     
   Mean ± SD                                  6.8 ± 1.7                         5.2 ± 2.9
   Median (range)                             8 (1--8)                          5.0 (1.0--9.0)

BMI: body mass index; BMI%: BMI percentile; CF: cystic fibrosis; PERT: pancreatic enzyme replacement therapy.

^a^ *N* = 13,739 (adult patients).

^b^ *N* = 5299 (pediatric patients).

^c^ Reflects PERT use prorated within each year of follow-up to account for years with partial use (e.g. due to treatment interruptions or missing data).

^d^ Reflects overall duration of PERT use regardless of partial use during follow-up years. Excludes follow-up years before a patient turned 21 years of age.

Hospitalization data {#section8-1479973119900612}
--------------------

### Cumulative longitudinal analysis {#section9-1479973119900612}

Cumulative longitudinal analysis indicated that the median annual HAR was 0.3 admissions per patient (range, 0--9.2; [Table 2](#table2-1479973119900612){ref-type="table"}) for all children and 0.78 admissions per patient (range, 0--13.5) for all adults. The median annual THN was 1.5 nights per patient (range, 0--203 nights; [Table 2](#table2-1479973119900612){ref-type="table"}) for children and 3.78 nights per patient (range, 0--245.5 nights) for adults. For children, the three most common reasons for hospital admission were pulmonary exacerbation (69%), gastrointestinal complication (9%), and pulmonary complication (3%). Approximately 80% of hospital admissions for adult patients were because of pulmonary exacerbation, followed by gastrointestinal complication and pulmonary complication.

###### 

HAR and total hospital nights per year.

![](10.1177_1479973119900612-table2)

                           Pediatric patients (*N* = 5301)   Adult patients (*N* = 13,989)                 
  ------------------------ --------------------------------- ------------------------------- ------------- -----------------
  Annual HAR per patient   0.5 ± 0.7                         0.3 (0--9.2)                    1.2 ± 1.4     0.78 (0--13.5)
  Annual THN per patient   4.4 ± 8.8                         1.5 (0--203)                    11.3 ± 19.2   3.78 (0--245.5)

HAR: hospital admission rate; THN: total hospital nights.

### Multivariate linear regression analysis {#section10-1479973119900612}

Multivariate analysis of patient-level data indicated that higher annual PERT use rate and longer cumulative PERT use rate were significantly (*p* \< 0.0001) associated with fewer annual hospitalizations and hospital nights in children and adults ([Table 3](#table3-1479973119900612){ref-type="table"}). Controlling for the other covariates (including cumulative PERT use, mean BMI% or BMI, and sex), each 10% absolute increase in mean annual PERT use rate in children was associated with a decrease of 0.11 admissions in the mean annual HAR and a decrease of 1.0 nights in the mean annual THN. In children, for each 1-year increase in the cumulative use of PERT, mean annual HAR decreased by 0.02 admissions and mean annual THN decreased by 0.56 nights. In adults, each 10% increase in the mean annual PERT use rate was associated with a decrease of 0.18 admissions in the mean annual HAR and a decrease of 2.4 nights in the mean annual THN. For each 1-year increase in the cumulative use of PERT in adults, there was a decrease in the mean annual HAR of 0.08 admissions and 1.2 fewer nights in mean annual THN.

###### 

Multivariate linear regression analysis of associations between HAR and total hospital nights per year with PERT use, BMI, and sex.^a^

![](10.1177_1479973119900612-table3)

  -------------------------------------------------------------------------------------------------------------------------------
  Factor                         Pediatric patients\           Adult patients\                                  
                                 Regression coefficient ± SE   Regression coefficient ± SE                      
  ------------------------------ ----------------------------- ----------------------------- ------------------ -----------------
  Mean annual PERT use rate^b^   −0.11 ± 0.007^e^              −1.00 ± 0.09^e^               −0.18 ± 0.005^e^   −2.37 ± 0.08^e^

  Cumulative use of PERT^c^      −0.02 ± 0.01^e^               −0.56 ± 0.08^e^               −0.08 ± 0.005^e^   −1.18 ± 0.07^e^

  Mean BMI^d^                    −0.03 ± 0.004^e^              −0.45 ± 0.05^e^               −0.09 ± 0.003^e^   −1.12 ± 0.04^e^

  Female versus male sex         0.04 ± 0.02^f^                0.47 ± 0.23^f^                0.13 ± 0.02^e^     0.74 ± 0.30^f^
  -------------------------------------------------------------------------------------------------------------------------------

BMI: body mass index; BMI%: BMI percentile; HAR: hospital admission rate; PERT: pancreatic enzyme replacement therapy; THN: total hospital nights.

^a^ Because cumulative PERT use has a linear relationship with age, this model does not include age.

^b^ A single unit change was defined as 10%.

^c^ A single unit change was defined as 1 year.

^d^ Mean BMI% was used for pediatric patients. A single unit change was defined as 10 percentile for pediatric patients or 1 kg/m^2^ for adult patients.

^e^ *p* \< 0.0001.

^f^ *p* \< 0.05.

Higher BMI% (children) or BMI (adults) was significantly (*p* \< 0.0001) associated with fewer annual hospitalizations and hospital nights in children and adults ([Table 3](#table3-1479973119900612){ref-type="table"}). Controlling for the other covariates, an increase of 10% in mean BMI% in children was associated with a reduction of 0.03 admissions in mean annual HAR and 0.45 nights in the mean annual THN. An increase of 1 kg/m^2^ in mean BMI in adults was associated with a reduction of 0.09 admissions in annual HAR and 1.1 nights in the mean annual THN. Female sex was significantly associated with more frequent and longer annual hospitalizations in children and adults. Compared with boys, girls had an increase in the mean annual HAR of 0.04 admissions and 0.47 more nights in mean annual THN. Compared with men, women had an increase in the mean annual HAR of 0.13 admissions and 0.74 more nights in mean annual THN.

### Cross-sectional analysis by age {#section11-1479973119900612}

In children, cross-sectional analysis by age revealed that BMI% was greatest at 5 years of age; the lowest HAR and THN occurred at 4 years of age ([Figure 2(a) and (b)](#fig2-1479973119900612){ref-type="fig"}). In adults, BMI increased steadily with age, whereas mean HAR and mean annual THN decreased with age; however, there was a peak between ages 40 and 45 years in HAR and annual THN ([Figure 2(c) and (d)](#fig2-1479973119900612){ref-type="fig"}). Boys and girls had differential annual HAR and THN starting at 8 and 9 years of age, respectively (*p* \< 0.05; [Figure 3](#fig3-1479973119900612){ref-type="fig"}), controlling for PERT use rates (mean, 83% in boys and girls; *p* = 0.7 for comparison).

![HAR (a) or total hospital nights (b) per year versus BMI percentile in pediatric patients by age or HAR (c) or total hospital nights (d) per year versus BMI in adult patients. BMI: body mass index; BMI%: BMI percentile; HAR: hospital admission rate.](10.1177_1479973119900612-fig2){#fig2-1479973119900612}

![HAR per year (a) and total hospital nights per year (b) in boys and girls by age. \**p* \< 0.05, boys versus girls. HAR: hospital admission rate.](10.1177_1479973119900612-fig3){#fig3-1479973119900612}

Discussion {#section12-1479973119900612}
==========

The results of this analysis of 19,290 children and adults with CF from the CFF Patient Registry indicate that among patients using PERT, self-reported adherence to PERT was associated with a reduction in annual hospital admissions and number of annual hospital nights. In addition, increasing BMI or BMI% was associated with a reduction in hospitalization and number of hospital nights. Notably, women and girls had higher annual HARs and more hospital nights than did men and boys; this sex-related difference was evident by approximately 8 to 9 years of age.

Treatment of patients with CF is complex; it involves numerous medications and is time-consuming for patients.^[@bibr20-1479973119900612]^ Because of these and other factors,^[@bibr9-1479973119900612]^ overall treatment adherence to CF medications in general is poor; adherence to PERT has been reported to range from 27% to 49%.^[@bibr21-1479973119900612],[@bibr22-1479973119900612]^ Poor treatment adherence to CF medications is associated with increased pulmonary exacerbations, hospitalizations, and health-care costs.^[@bibr10-1479973119900612],[@bibr11-1479973119900612]^ The cost of hospitalizations as a proportion of total CF-related health-care spending varies widely (e.g. ranging from 12% to 77%) according to country and patient characteristics.^[@bibr23-1479973119900612],[@bibr24-1479973119900612]^ In the United States, an analysis of the 2007 Nationwide Inpatient Sample database estimated that total hospital charges for adults (18--44 years) with CF averaged US\$ 53,095 to US\$ 59,627, depending on the type of hospital.^[@bibr25-1479973119900612]^ Thus, reducing CF-related hospitalizations might be expected to reduce overall CF-related health-care costs.

In patients with CF, good nutritional status is associated with improved lung function,^[@bibr7-1479973119900612],[@bibr26-1479973119900612]^ survival,^[@bibr8-1479973119900612]^ and increased health-related quality of life.^[@bibr27-1479973119900612]^ In this retrospective analysis, increased BMI or BMI%, which was used as a surrogate for nutritional status, was associated with a reduction in hospitalization admissions and number of hospital nights. In children, there was an inverse curvilinear relationship between BMI% and hospitalization. In adults, BMI continued to increase linearly over time, possibly as the result of the long-term survival of those patients who had better nutritional status; a potential contributing factor that was not measured is that these patients may have had milder genotypes and subsequently less pancreatic insufficiency. These results are consistent with a number of studies showing that nutritional status, especially in early childhood, has a major impact on pulmonary function and mortality. For example, in children with CF, better nutritional indices at 3 years of age were associated with better lung function at 6 years of age compared with poorer nutritional indices.^[@bibr28-1479973119900612]^ In an analysis of the 2007 European Cystic Fibrosis Society Patient Registry database, BMI was positively associated with lung function in both children and adults; patients with a low BMI had a sixfold greater risk, compared with patients with normal BMI, of having a forced expiratory volume in 1 second measurement that was \<40% of the predicted value.^[@bibr29-1479973119900612]^ Finally, in children with CF, weight-for-age percentile \>50% at 4 years of age was associated with better lung function, fewer CF-related complications, fewer annual hospital nights, and lower mortality at 18 years of age than children with a weight-for-age percentile \<50% at 4 years of age.^[@bibr8-1479973119900612]^

In our analysis, girls had a higher annual hospitalization rate and more total hospital nights per year than boys, starting at 8 and 9 years of age, respectively. Moreover, adult female patients had a slightly but significantly increased annual hospitalizations and more hospital nights per year compared with adult male patients. These results are consistent with an analysis using the Canadian CF Patient Registry that showed greater rates of hospitalization in female patients than in male patients aged 7 to 19 years and ≥20 years.^[@bibr30-1479973119900612]^ The reasons for these sex-related differences are unclear. Previous studies have reported that compared with boys with CF, adolescent girls with CF have a lower adherence to some aspects of CF management, including coughing as an airway clearance technique, consumption of high-calorie, high-fat foods, and taking medications.^[@bibr31-1479973119900612],[@bibr32-1479973119900612]^ Differences in caloric intake may be related to perceived body image and self-esteem, with female patients with CF preferring a lower BMI than male patients.^[@bibr33-1479973119900612],[@bibr34-1479973119900612]^ Girls and women also reported more CF-related emotional and physical strains than boys and men.^[@bibr32-1479973119900612],[@bibr33-1479973119900612]^

This study has several limitations. It was an observational retrospective study of open-label treatment, without randomization or stratification, and was thus subject to various kinds of bias and confounding factors. Although occasional outliers from the typical demographic profile of patients with CF were observed (e.g. age of 82 years or BMI of 44.8 kg/m^2^), the large analysis sample sizes prevented skewing of the overall results. The need for exclusion of anomalous data such as more total annual hospital nights than days in a year highlights the fact that data from registries, though invaluable, require curation to identify potential reporting errors. In this study, use of PERT was interpreted as indicating pancreatic insufficiency. Because the CFF registry does not capture pancreas status, it is possible some patients may have received PERT despite having sufficient pancreatic function due to more mild genotypes. In addition, self-reported PERT use rates (extrapolated from the percentage of CF center outpatient visits per year with PERT use recorded for each patient) may not accurately reflect actual daily PERT utilization and may be subject to data entry error or center-to-center variations in data collection and reporting. Adherence may have been influenced by the number of health-care provider visits, whereby more visits equal more data points, as well as by the "white coat phenomenon" of increased adherence as visits approach or with more frequent HCP visits. Moreover, among patients using PERT, higher self-reported PERT adherence may have been associated with better adherence to other medications and lifestyle modifications/management techniques, which could have contributed to reduced hospitalization. Of note, adherence to pulmonary medications was not measured in this analysis. Therefore, it could not be determined what impact adherence to pulmonary medications may have had on hospitalizations. By intention, no analyses were conducted for adolescent patients aged 14 to 19 years (*n* = 12,074). However, a recent study reported that adherence rates to pulmonary medications in CF were greatest in patients aged 6 to 10 years (59%) and decreased to approximately 40% to 50% in older children and adults.^[@bibr11-1479973119900612]^ Thus, in patients with CF, if PERT adherence is similar to adherence to pulmonary medications, we would not expect the results in patients aged 14 to 19 years to be substantially different from those presented for the age-groups in this report. Finally, this analysis identified both PERT and BMI or BMI% as statistically significant factors in reduced hospitalizations. PERT is prescribed specifically to address malnutrition caused by pancreatic insufficiency and to improve nutritional status (which would be reflected in BMI/BMI%); therefore, confirmatory analysis of the relationship between self-reported PERT adherence and BMI/BMI% could provide valuable information regarding the overall effect of PERT as a contributing factor in reduced hospitalizations related to improved nutritional status.

The results of this analysis among patients using PERT show the importance of adherence to PERT and of nutritional status in reducing the risk of hospitalization in children and adults with CF. Although there are certainly other contributing factors, self-reported adherence to PERT and increased BMI were associated with a reduction in hospitalization rate and annual number of hospital nights, thus reinforcing the close association between nutritional status and CF-related outcomes that needs to be communicated to patients with CF. Strategies to improve PERT adherence may provide benefits related to hospitalization in patients with CF.
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